ScoreWhy is Captor Therapeutics SA ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Poor long term growth as Operating profit has grown by an annual rate 2.49% of over the last 5 years
3
The company has declared Negative results for the last 6 consecutive quarters
- NET SALES(HY) At PLN 0.37 MM has Grown at -93.31%
- OPERATING CASH FLOW(Y) Lowest at PLN -71.61 MM
- ROCE(HY) Lowest at -128.86%
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 127.30%, its profits have fallen by -7.4%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Captor Therapeutics SA for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Captor Therapeutics SA
127.3%
0.17
43.80%
Poland WIG
29.57%
1.72
17.21%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-15.19%
EBIT Growth (5y)
2.49%
EBIT to Interest (avg)
-57.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.57
Sales to Capital Employed (avg)
0.25
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
40.37
EV to EBIT
-8.77
EV to EBITDA
-9.49
EV to Capital Employed
-127.31
EV to Sales
197.70
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-353.85%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at PLN -21.42 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -121.9 %
-15What is not working for the Company
NET SALES(HY)
At PLN 0.37 MM has Grown at -93.31%
OPERATING CASH FLOW(Y)
Lowest at PLN -71.61 MM
ROCE(HY)
Lowest at -128.86%
RAW MATERIAL COST(Y)
Grown by 1,016.22% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 0.76 times
EPS(Q)
Lowest at PLN -2.1
Here's what is working for Captor Therapeutics SA
Net Profit
Higher at PLN -21.42 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (PLN MM)
Debt-Equity Ratio
Lowest at -121.9 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Captor Therapeutics SA
Net Sales
At PLN 0.37 MM has Grown at -93.31%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (PLN MM)
Operating Cash Flow
Lowest at PLN -71.61 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (PLN MM)
EPS
Lowest at PLN -2.1
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (PLN)
Debtors Turnover Ratio
Lowest at 0.76 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 1,016.22% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
